Shake­up at the top of FDA’s biosim­i­lars di­vi­sion as Leah Christl de­parts for Am­gen

The FDA on Fri­day an­nounced that Leah Christl, di­rec­tor of the Ther­a­peu­tic Bi­o­log­ics and Biosim­i­lars Staff (TBBS) in the Of­fice of New Drugs (OND), has de­cid­ed to leave the FDA and will de­part 22 Feb­ru­ary. Christl is mov­ing to Am­gen.

Am­gen told Fo­cus Christl will be join­ing as ex­ec­u­tive di­rec­tor, glob­al reg­u­la­to­ry and R&D pol­i­cy on 11 March.

Af­ter join­ing the FDA in 2003, Christl since 2010 has been at the fore­front of biosim­i­lar pol­i­cy and reg­u­la­tions at the FDA and was the lead ex­pert in both of the user fee agree­ments for biosim­i­lars.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER